NCT02373280 The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
| NCT ID | NCT02373280 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Bundang Hospital |
| Condition | Helicobacter Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2014-08 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2014-08 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.
Eligibility Criteria
Inclusion Criteria: * The patients who proved H. pylori infection following three methods 1. positive rapid urease test (CLOtest) 2. histologic evidence of H. pylori by modified Giemsa staining 3. positive Urea breath test * Male and female Korean Adult (Aged ≥ 18 years) Exclusion Criteria: * Patients who received eradication therapy for H. pylori infection, previously * H. pylori eradication failure because of poor compliance * the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks * Advanced gastric cancer or other malignancy * Abnormal liver function or liver cirrhosis * Abnormal renal function or chronic kidney disease * Other severe concurrent diseases * Previous allergic reactions to the study drugs * Pregnant or lactating women
Contact & Investigator
Nayoung Kim, M.D., Ph. D
PRINCIPAL INVESTIGATOR
Seoul National University Bundang Hospital
Frequently Asked Questions
Who can join the NCT02373280 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Helicobacter Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02373280 currently recruiting?
Yes, NCT02373280 is actively recruiting participants. Contact the research team at nayoungkim49@empas.com for enrollment information.
Where is the NCT02373280 trial being conducted?
This trial is being conducted at Seongnam-si, South Korea.
Who is sponsoring the NCT02373280 clinical trial?
NCT02373280 is sponsored by Seoul National University Bundang Hospital. The principal investigator is Nayoung Kim, M.D., Ph. D at Seoul National University Bundang Hospital. The trial plans to enroll 600 participants.